Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.
Sponsor:
University of California, San Francisco
Phase:
Phase 2
Contacts:
Maya Aslam (CONTACT)maya.aslam@ucsf.edu
(415) 514-8987
Thomas Hope, MD (PRINCIPAL_INVESTIGATOR)Government Study Link:
NCT06961084 - Click here to see study onClinicalTrials.gov
Exclusion Criteria Not Yet Provided
Help us improve your experience